Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Medtronic
McKinsey
Dow
Baxter

Last Updated: April 10, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GAZYVA

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for GAZYVA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02100852 TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) Active, not recruiting TG Therapeutics, Inc. Phase 1 2014-03-01 The purpose of this study is to evaluate the safety and effectiveness of TGR-1202 in combination with obinutuzumab (Gazyva) and chlorambucil in patients with chronic lymphocytic leukemia.
NCT02225275 Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting Celgene Corporation Phase 2 2016-03-01 The goal of this clinical research study is to learn if the combination of lenalidomide and obinutuzumab can help to control CLL or SLL. The safety of this drug combination will also be studied.
NCT02225275 Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting Genentech, Inc. Phase 2 2016-03-01 The goal of this clinical research study is to learn if the combination of lenalidomide and obinutuzumab can help to control CLL or SLL. The safety of this drug combination will also be studied.
NCT02225275 Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Recruiting M.D. Anderson Cancer Center Phase 2 2016-03-01 The goal of this clinical research study is to learn if the combination of lenalidomide and obinutuzumab can help to control CLL or SLL. The safety of this drug combination will also be studied.
NCT02292225 Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) Recruiting Infinity Pharmaceuticals, Inc. Phase 1 2015-02-01 To evaluate the safety, pharmacokinetics, and pharmacodynamics of Duvelisib (IPI-145) in combination with obinutuzumab in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi.
NCT02371590 Lenalidomide and Obinutuzumab for Previously Untreated CLL Not yet recruiting Celgene Corporation Phase 2 2017-06-01 This is phase 1/2 study for patients with CLL or (SLL) who have not been previously treated. This study will evaluate whether obinutuzumab and lenalidomide is safe and tolerable in this setting and induce complete clinical responses.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for GAZYVA

Condition Name

Condition Name for GAZYVA
Intervention Trials
Chronic Lymphocytic Leukemia 14
Small Lymphocytic Lymphoma 4
Chronic Lymphocytic Leukemia (CLL) 3
Follicular Lymphoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for GAZYVA
Intervention Trials
Lymphoma 22
Leukemia, Lymphoid 21
Leukemia, Lymphocytic, Chronic, B-Cell 21
Leukemia 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for GAZYVA

Trials by Country

Trials by Country for GAZYVA
Location Trials
United States 95
Italy 9
Australia 6
Canada 5
Spain 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for GAZYVA
Location Trials
Texas 10
California 6
Ohio 5
New York 5
Massachusetts 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for GAZYVA

Clinical Trial Phase

Clinical Trial Phase for GAZYVA
Clinical Trial Phase Trials
Phase 3 7
Phase 2 18
Phase 1/Phase 2 4
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for GAZYVA
Clinical Trial Phase Trials
Recruiting 21
Not yet recruiting 17
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for GAZYVA

Sponsor Name

Sponsor Name for GAZYVA
Sponsor Trials
Genentech, Inc. 11
National Cancer Institute (NCI) 10
M.D. Anderson Cancer Center 6
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for GAZYVA
Sponsor Trials
Other 33
Industry 30
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Merck
Johnson and Johnson
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.